Search results
516 results
-
Osstem Implant Enhances OneClick Electronic Chart with AI Features Osstem Implant is accelerating the digital transformation of dental care by expanding the AI capabilities of its OneClick electronic chart. The aim is to reduce the workload of medical staff by allowing them to manage patient records, image interpretations, and patient interactions all within a single chart. On June 11, Osstem Implant announced enhancements to OneClick, including improved panoramic diagnostic features and the integration of AI technologies such as motion detection and speech-to-text (STT). The company emphasized that these upgrades focus on practical functionalities needed in clinical settings. The electronic chart system manages patient information, medical history, images, and questionnaires in digital format. It addresses limitations of paper charts, such as handwriting recognition issues and information omissions, thereby alleviating the burden on clinical staff. Osstem Implant has been refining OneClick since its beta version was launched in 2020. Among the newly added features, the most notable is the AI capability to analyze the risk of cavities. The company plans to introduce a system later this year that will assess diagnostic images and analyze the risk of cavities. This system is designed to assist medical staff in identifying areas they might overlook and to facilitate more intuitive explanations during patient consultations based on the big data the company has accumulated. Convenience features tailored to the clinical environment are also being enhanced. Motion detection technology allows for searching and inputting information without the need for mouse clicks or keyboard typing, enabling staff to interact with the system using hand gestures even while wearing gloves. The STT feature distinguishes between the dentists and patients conversations, automatically extracting key information and recording it in the electronic chart. An Osstem Implant representative stated, Expanding AI-based clinical support functions is an effort to enhance the accuracy and efficiency of dental care. We will continue to introduce digital solutions that both medical staff and patients can benefit from. Meanwhile, the adoption of AI in the pharmaceutical and bio sectors, as well as in hospitals, is accelerating the digital transformation of the medical field. AI is playing a supportive role in various areas, including image interpretation, medical record management, prescription processing, and implant procedures, leading to improvements in diagnostic accuracy and efficiency. Industry insiders noted, The impact of AI adoption by major companies is evident in improved diagnostic accuracy, reduced patient consultation times, and decreased workload for medical staff.* This article has been translated by AI. June 11, 2026 10:45 -
K-Content Expands in Europe with 40,000 Attendees in LA The Korea Creative Content Agency announced that the 2026 K-EXPO FRANCE: All about K-Culture will take place from June 16 to 19 at the Palais des Congrès and Le Méridien Étoile hotel in Paris. This event aims to expand the success of the K-Expo held in Los Angeles last month, which attracted over 40,000 visitors in just two days. The LA event broadened its scope beyond K-Pop and content to include food, beauty, and various aspects of K-style. Domestic companies engaged in over 500 business consultations and signed more than 30 agreements with local firms. From June 16 to 18, the Palais des Congrès will host a business-to-consumer (B2C) exhibition featuring K-Pop performances. Netflix Korea will showcase collaborations with major domestic companies such as Kumho Tire, Kia, and Nongshim. Twelve AI content companies, including CJ ENM, will present the latest AI content in a cinema concept. Attendees can experience interactive content based on extended reality (XR), augmented reality (AR), and AI in the K-Tech Connect area. The K-Beauty Boutique will feature the Korea Cosmetic Industry Institute, the only research institution specializing in cosmetics in the country, along with companies like Cosway and Fusion Bio, presenting the latest trends in K-Beauty. The K-Food Market will include participation from the Korea Agro-Fisheries & Food Trade Corporation and Nongshim, offering experiences such as tasting Han River ramen, seafood products, and demonstrations of easy-to-prepare rice tteokbokki, showcasing the diversity of K-Food. In the K-Collaboration Zone, attendees can experience the fusion of Korean technology and tradition with the European luxury industry. The Ice Staging exhibition will vividly recreate the collaboration between traditional Korean mother-of-pearl artisans, contemporary art sensibilities, and the French luxury fashion brand Louis Vuitton using XR and virtual reality (VR) technologies. On the evening of June 17, the K-Pop Concert: Inkigayo in Paris will feature six K-Pop artist groups, including SHINees Taemin, MONSTA X, NCT Wish, 82Major, Stella Jang, and Hats to Hearts, at the Palais des Congrès. From June 18 to 19, Le Méridien Étoile hotel will host an export consultation meeting for businesses. Forty-six domestic companies will participate, engaging in one-on-one export consultations with over 100 major broadcasting, webtoon, distribution, and OTT companies in Europe. June 11, 2026 09:42 -
NH Investment & Securities Raises Target Price for Samsung C&T Amid Growth Prospects NH Investment & Securities announced on June 11 that it has raised its target price for Samsung C&T from 425,000 won to 550,000 won, citing expectations for increased high-tech construction orders and growth in nuclear power and small modular reactor (SMR) projects, along with an anticipated expansion in shareholder returns. The firm also noted a higher likelihood of dividend increases and maintained its investment recommendation at buy. Lee Seung-young, a researcher at NH Investment & Securities, stated, The construction sector is expected to see increased high-tech orders, such as those for the Pyeongtaek P5 project, due to expanded investments from clients. We anticipate that high-tech sales will begin to ramp up in the second half of this year, leading to improved profitability. He added, We are pursuing the expansion of large-scale nuclear power and SMR projects, participating in various initiatives including Vietnams second nuclear power plant, Romanias Units 3 and 4, Saudi Arabias nuclear project, Romanias SMR, and Swedens SMR. The researcher explained, Our performance is steadily growing based on a diversified portfolio that includes construction, bio, and trading sectors. Currently, the stock price is trading at a 55.7% discount to its net asset value (NAV). He also mentioned, According to the shareholder return policy for 2026 to 2028, we plan to return 60% to 70% of the dividend income from affiliates to shareholders. The special dividend from Samsung Electronics and the increased dividends from Samsung Life Insurance could lead to a rise in Samsung C&Ts dividend income. Furthermore, he noted, We have adjusted the target NAV discount from 45% to 40% to reflect the rising value of investment assets such as Samsung Electronics and Samsung Life Insurance, leading to the upward revision of the target price. We also expect additional shareholder returns based on expanded dividend income in the future.* This article has been translated by AI. June 11, 2026 09:21 -
Celltrion Expands Collaboration with Seoul Bio Hub for Bio Startup Support Celltrion is expanding its collaboration with the Seoul Bio Hub to enhance its bio startup discovery and partnership program. The company has selected four startups with next-generation technologies, including AI-based protein antibody development, organoids, disease modeling, and oral delivery formulations, for its fourth phase of the Open Innovation Program. This initiative is expected to contribute to the ongoing growth of the domestic biotech ecosystem.On June 10, Celltrion announced the final selection of four companies for the fourth phase of the 2026 Seoul Bio Hub-Celltrion Open Innovation Program.The selected companies include: 1) AINB, which specializes in AI-based protein antibody development; 2) EnbioCell, which focuses on a GLP-1 derivative oral delivery formulation platform based on ChargeSmed; 3) Imita Science, known for its biomimetic tissue-based disease modeling and drug evaluation technology; and 4) Podotherapeutics, which offers a precision medicine platform based on patient-derived organoids (PDO).These companies were chosen after a thorough evaluation by a review panel that included external technology assessors. The four startups will receive tailored support at various stages of growth, including joint research and commercialization opportunities, technology advancement, and mentoring from Celltrion.A Celltrion representative stated, This program aims to discover biotech and medical startups with innovative technologies that can align with Celltrions research and development needs, and to support technology advancement and growth through collaboration with the Seoul Bio Hub. The company plans to assist the growth of promising firms and expand the collaborative foundation of the domestic biotech ecosystem.Since 2020, Celltrion has participated as a private operator in the Incheon Startup Park development project. Additionally, it is involved in the K-Bio Lab Hub construction project, leading efforts to discover and nurture promising companies through its open innovation strategy.* This article has been translated by AI. June 10, 2026 17:51 -
President Lee to Hold Summit with Belgium and EU, Strengthening Diplomatic Ties President Lee Jae-myung is set to hold a series of summits with Belgium and the European Union (EU) on June 10, 2026. The president is on a European tour coinciding with the G7 summit. He will first meet with Belgian Prime Minister Alexander De Croo in the morning, followed by a meeting with King Philippe. This marks the first meeting between the leaders since Lee took office, with discussions expected to focus on enhancing trade and expanding cooperation with small and medium-sized enterprises. The Blue House noted that Belgium, with its logistics hub centered around Antwerp, the EUs second-largest port, and its developed chemical and bio-cluster industries, presents opportunities for Korean companies to establish a foothold in Europe. In the afternoon, President Lee will meet with António Costa, the President of the European Council, and Ursula von der Leyen, the President of the European Commission. This visit marks the first time in eight years that a South Korean president has traveled to Brussels for bilateral diplomacy with the EU, signifying a renewed focus on European relations based on the achievements of the past year. The discussions will likely cover strengthening economic exchanges with the EU, as well as expanding cooperation in security areas such as drug trafficking, terrorism, and transnational crime. Additionally, the agenda is expected to address the situation on the Korean Peninsula and in the Middle East, along with strategies for energy and mineral supply chain collaboration.* This article has been translated by AI. June 10, 2026 15:42 -
Emerging Bio Startups Focus on Personalized Medicine and Innovative Treatments Seoul City is collaborating with major biotech firms to nurture promising bio startups, drawing attention to the technological capabilities of the selected companies. While biotechnology may seem complex, these innovative firms are focused on transforming injections into pills, developing new drugs without animal testing, and identifying personalized medications for patients in advance. One standout is EnbioCell, selected in the fourth round by Celltrion. The company is developing a technology to convert GLP-1 class obesity treatments, which currently require injections, into oral medications. While these treatments are effective, the burden of self-injection can be significant for patients. EnbioCell aims to tackle this challenge with its proprietary technology that enhances absorption in the body while resisting stomach acid and digestive enzymes. If successful, this could greatly improve patient compliance and attract global market interest. AINB is leveraging artificial intelligence (AI) to design new drug candidates. Traditional drug development often involves a lengthy process of repeated experiments to identify potential candidates. However, AINB uses computer simulations to predict antibody structures that best bind to disease proteins, effectively acting as an AI that selects promising drug candidates. This approach has the potential to significantly reduce drug development costs. Imita Science exemplifies the future direction of biotechnology with its focus on animal-free drug development. The company utilizes organ-on-a-chip technology that mimics human organ environments to verify drug efficacy and toxicity in advance. By obtaining data from human cell-based environments instead of traditional animal testing, the company aims to enhance clinical success rates. This technology is gaining traction in the global pharmaceutical industry due to ethical and cost considerations. Podotherapeutics, with its innovative organoid technology, cultivates stem cells extracted from patient tissues to create mini-organs in the lab. This allows for testing which drugs are most effective for individual patients before administering treatment, marking a significant step toward personalized precision medicine. Daewon Pharmaceutical has also selected intriguing companies. OmniaMed is developing a smart drug delivery system that releases medication only when specific substances, often found in cancerous tissues or inflamed areas, are detected. This aims to minimize common side effects of cancer treatment, such as hair loss and vomiting, by concentrating the drugs effects on the targeted lesions. CurioSabioScience possesses a platform technology that helps maintain consistent drug efficacy in the body over extended periods. The company is working on technologies to convert injections into oral medications that provide long-lasting effects, thereby reducing patient dosing burdens and enhancing global commercialization potential. Industry experts view the selected companies as pushing the boundaries of existing biotechnology. Seoul City, along with Celltrion and Daewon Pharmaceutical, will support joint research and commercialization verification over the next year. The initiative aims to combine the research capabilities of large corporations with the innovative technologies of startups to cultivate global biotech unicorns. Lee Soo-yeon, Director of the Economic Office at Seoul City, stated, The open innovation at Seoul Biohub serves as a ladder for startups to gain experience and networks from global anchor companies, while providing large corporations with a platform to secure innovative technologies. We will spare no effort in supporting the selected startups to grow into unicorn companies that lead the global biotech market beyond South Korea. June 10, 2026 13:03 -
Hugel Showcases Key Products at AMWC KOREA, Highlighting K-Aesthetic's Global Status Hugel will unveil its major product portfolio at the AMWC KOREA, the first global aesthetic medical conference held in South Korea. This event is seen as an opportunity to showcase the global status of K-Aesthetic.From June 19 to 20, Hugel will participate in the Aesthetic & Anti-aging Medicine World Congress KOREA (AMWC KOREA) at the Grand InterContinental Seoul Parnas.At the event, Hugel will have a dedicated booth featuring key products including botulinum toxin, Letybo, HA fillers, Revolax bioregenerative skin boosters, HA (BYRYZN) sutures, and Licellvi.On June 19, a lunch symposium will feature presentations from Kim Se-jin, director of Myeongdong Liens Plastic Surgery Clinic, and Jang Hyo-seung, director of the Gangnam Pierbom Clinic, who will share their clinical experiences and insights on toxin procedures. Following this, Dr. Suneel Chilukuri, founder of Refresh Dermatology in the U.S., will present his experiences and clinical cases involving Letybo treatments in the United States.In addition to the conference, Hugel plans to offer various programs that allow participants to experience the medical aesthetic scene in Korea. From June 17 to 18, the AMWC KOREA with L.E.A.D educational program will include clinic tours and live demonstrations, followed by the Hugel Lead Night networking event for global medical professionals on the final day, June 20.Carrie Strom, Hugels global CEO, stated, AMWC KOREA is expected to be a meaningful opportunity for Hugels clients and employees to gather and share market experiences and insights from various regions, enhancing global business synergy.Meanwhile, as the global status of K-Aesthetic rises, Hugel reported simultaneous growth in revenue and profitability in the first quarter of this year, driven by expansion in overseas markets.Specifically, Hugel recorded consolidated revenues of 116.6 billion won, operating profit of 47.6 billion won, and net profit of 40.6 billion won for the first quarter. Compared to the same period last year, revenues increased by 29.9%, operating profit by 22.3%, and net profit by 31.5%. Notably, the operating profit margin stood at 40.8%, reflecting strong profitability.* This article has been translated by AI. June 10, 2026 12:15 -
Samsung Electronics Becomes Largest Shareholder in Element Biosciences Samsung Electronics has secured its position as the largest shareholder in Element Biosciences, a U.S. genetic analysis equipment company. This move is part of the companys strategy to focus on artificial intelligence (AI) and digital health as key drivers for future growth in next-generation precision medicine technologies.On June 10, Samsung announced its participation in Elements Series E funding round, investing an additional $175 million. This investment, combined with last years Series D funding, has made Samsung the largest shareholder in Element, although no changes in management control are expected.The investment primarily targets genomic analysis and multiomics technology. Multiomics integrates various biological data, including DNA, RNA, and proteins, to identify disease causes and aid in drug development, positioning it as a next-generation precision medicine technology.Founded in 2017 in San Diego, Element boasts DNA sequencing technology with an accuracy level of 99.99%. The company has emerged as a strong player in the next-generation sequencing market by reducing costs while enhancing accuracy.Element is developing multiomics technology that integrates various biological data into a single platform, moving beyond traditional methods that analyze DNA, RNA, and proteins separately. In 2022, Element launched its DNA sequencing device, AVITI, followed by AVITI24, which analyzes cellular changes over time. Future products include VITARI, which aims to significantly increase analysis capacity while reducing costs, and AVITI Dx, designed for clinical diagnostics.Samsung plans to combine its expertise in AI, medical devices, and digital health with Elements genomic analysis technology to target the next-generation genetic diagnostics and personalized healthcare markets. There is potential to expand into personalized healthcare services by integrating DNA sequencing data with health data collected from wearable devices.Molly He, CEO of Element, stated, Samsungs increased investment in Element demonstrates deep trust in our vision, technology, and team. Through this investment, we will continue to promote scientific discovery and deliver innovative technologies that enhance human health.Lee Tae-moon, President of Samsung Electronics, emphasized, The synergy created by combining Samsungs expertise in AI, medical devices, and digital health with Elements innovative genomic analysis technology will pave the way for the future of personalized medicine. Samsung will continue to invest across a wide range of areas, from precision medical devices to digital health, with the goal of improving peoples health. June 10, 2026 08:39 -
Pulmuone Breaks Ground on Korea's First Land-Based Seaweed R&D Center Pulmuone has announced the construction of Koreas first land-based seaweed research and development (R&D) center in the Saemangeum National Industrial Complex, aiming to foster the future of the seafood industry. On June 9, Pulmuone revealed that it has begun construction on the Seaweed Land-Based Aquaculture R&D Center in Saemangeum, which is part of a national project led by the Ministry of Oceans and Fisheries to develop sustainable high-quality seaweed seed production and land-based aquaculture technology. The center will serve as a hub for demonstrating year-round seaweed production technology and developing industrialization models. The center will cover a total area of 9,473 square meters (approximately 2.86 acres) and will be equipped with integrated research infrastructure, including aquaculture facilities, seawater intake and discharge systems, and research and support facilities. In the first phase of the project, key facilities such as the seaweed aquaculture building, seawater treatment facilities, and office buildings will be established, with plans for a second phase expansion based on the results of the initial demonstrations. The second phase will include the construction of additional aquaculture buildings, storage facilities, processing units, and research buildings, significantly expanding the centers capacity. Notably, it will feature the countrys largest bio-reactor-based aquaculture system, which allows for precise control of temperature, light, and nutrients to enable stable seaweed production indoors. Pulmuone plans to establish a one-stop industrialization system that encompasses the entire process from production to processing and distribution. The company is also accelerating the development of a regional coexistence model. Pulmuone intends to share the aquaculture technology and industrialization models developed at the R&D center with local governments and regional fishers, aiming to expand these practices to nearby aquaculture complexes. The structure will ensure that all seaweed produced in these complexes is purchased by Pulmuone, creating a stable income source for the region while securing a supply chain for the company. Since starting seaweed seed research in 2006, Pulmuone became the first private company to obtain seaweed variety protection rights in 2014 and began full-scale development of land-based aquaculture technology in 2021. Last year, the Ministry of Oceans and Fisheries recognized Pulmuones expertise by selecting it as the final contractor for a five-year, 35 billion won seaweed land-based aquaculture technology development project. The company is currently conducting demonstration research on land-based aquaculture technology in Osong, North Chungcheong Province, and Taean, South Chungcheong Province. Anduk-jun, head of Pulmuones food tech division, stated, The Saemangeum R&D center will be a crucial turning point for demonstrating and establishing the industrialization foundation of seaweed land-based aquaculture technology. We aim to build a sustainable seafood model based on food tech innovation capabilities and lead the global market in the future seafood industry. Land-based seaweed aquaculture is a technology that artificially replicates marine environments indoors to produce seaweed. It is gaining attention as next-generation aquaculture technology due to its reduced vulnerability to climate change and ocean environmental shifts, as well as its ability to maintain consistent quality.* This article has been translated by AI. June 9, 2026 23:51 -
Korean Innovative Companies Hold Investment Roadshow in Chengdu, China Korean innovative companies held an investment roadshow in Chengdu, Sichuan Province, to engage with local businesses and investors for potential collaborations. The Korean Innovation Companies Roadshow K-Demo Day took place on June 9, co-hosted by the Global Innovation Center (KIC China), KIST Innovation, the Chengdu High-tech Zone Science and Technology Innovation Bureau, and the National Technology Transfer Center of Southwest China. Twelve domestic innovative companies from the bio, medical device, semiconductor, and artificial intelligence sectors participated in the event. The participating companies included Alt Medical, Ready Cure, Near Brain, True Pixel, Gopher Soft, Cross Hub, Depot Lab, Gensel Med, Dayton, Aid All, EMS, and Megazone. These firms introduced their core technologies and business models to investors and industry stakeholders, exploring opportunities for technological exchange and collaboration between Korea and China. The event attracted over 180 attendees, including government officials, academics, and industry representatives. Chinese participants included officials from the Chengdu city government, local businesses, and investment institutions, who engaged in business consultations and networking with the Korean companies. Attendees shared insights on the technological competitiveness of the bio and medical device sectors and discussed collaboration strategies for clinical and regulatory approvals. They also explored the market expansion potential of the semiconductor and ultra-precision component industries, which are expected to lead the AI and metaverse era, as well as future strategies for information and communication technology (ICT) development. Kim Jong-moon, head of KIC China, stated, To address the complex challenges in the bio and semiconductor fields, collaboration that combines the excellent technological capabilities and market accessibility of both countries is essential. KIC China plans to expand technological business in the Chengdu-Chongqing economic zone and support technology cooperation between Korean and Chinese innovative companies through both online and offline channels.* This article has been translated by AI. June 9, 2026 16:48 -
Ministry of SMEs selects 5,000 participants for 'Everyone's Startup Project,' 68% are youth The Ministry of SMEs and Startups has finalized the selection of 5,000 participants for its Everyones Startup Project. According to the ministry on June 9, the project attracted a record 63,000 applicants nationwide, regardless of age, experience, or region, marking the largest government competition to date. Within just 37 days of its launch, the number of participants surpassed 20,000, indicating its popularity. Among the selected 5,000 participants, 68.4% are under the age of 39. The youngest selected participant is 13 years old, while the oldest is 78, showcasing a diverse range of entrepreneurial enthusiasm across generations. In the general and technology track, 4,000 participants were chosen. The youngest, 13-year-old Kim Tae-in, proposed a safety system that detects repeated school violence using only Wi-Fi signals. The oldest selected participant, at 78, suggested eco-friendly naphtha manufacturing technology utilizing food waste carbonization. An international participant proposed the development of an AI-based manuscript practice application for the TOPIK writing test. The local track selected 1,000 participants. The youngest, at 17, proposed a regular check-in service linked to the community, while the oldest, at 72, suggested developing a K-apple energy powder stick that melts without water, based on upcycling ugly apples from Gyeongbuk. An international participant proposed a travel information platform for Japanese tourists visiting Busan. Seventy-four percent of the selected participants are from local regions, with 70% from the general and technology track and 90% from the local track, highlighting a variety of innovative ideas from across the country. In terms of fields, the IT sector accounted for the largest share at 32% in the general and technology track, followed by lifestyle at 17.8%, and bio-medical at 10.1%. In the local track, lifestyle ideas made up 48.2%, followed by food and beverage at 37.3%, and beauty at 9.3%. Notably, 29.3% of the selected items in the general and technology track included AI-related keywords, indicating the spread of AI across various industries. Mentoring organizations such as CNT Tech and the Seoul Creative Economy Innovation Center, which oversaw the selection process, noted that entrepreneurship is not limited to specific demographics or technical fields. The 5,000 selected startup talents will receive support for their entrepreneurial journeys. Each participant will receive 2 million won in startup funding, along with initial mentoring from reputable organizations and AI solutions to rapidly enhance their business ideas. For the 58,000 applicants who were not selected in the first phase of the project, feedback from the mentors who evaluated their ideas will be provided. They will also have access to online and offline mentoring programs to refine their ideas. Offline mentoring sessions will begin on June 22 and will be held across 17 cities and provinces, with a total of 40 sessions scheduled to accommodate participants who may have difficulty attending during the week. Participants will receive one-on-one expert consulting and business model training to enhance their ideas. Applications will open on June 12. Online mentoring will be available through the Everyones Startup Platform starting June 22. Participants can choose their preferred mentors for one-on-one online sessions, which will be offered three times. To ensure a second chance, participants in the online and offline mentoring programs, as well as those who improve their ideas compared to their original submissions, will receive preferential treatment in the selection evaluation for the second phase of the Everyones Startup Project, set to launch in early July. This phase will select 10,000 participants, double the number from the first phase. Minister Han Seung-sook stated, We will fully support the 5,000 ideas selected in the first phase of the Everyones Startup Project to help them take flight and grow. For the 58,000 applicants who were not selected, we will establish a more robust entrepreneurial ladder in South Korea through systematic support for their reapplication efforts.* This article has been translated by AI. June 9, 2026 13:42 -
Pharmgen Science Expands into Regenerative Medicine and Biopharmaceuticals with TS Bio Partnership As the global regenerative medicine market continues to grow, Pharmgen Science is seeking to secure new growth drivers through this sector. On June 9, Pharmgen Science announced that it has signed a memorandum of understanding (MOU) with TS Bio to expand its business into regenerative medicine and biopharmaceuticals. This agreement is part of a strategic collaboration aimed at leveraging Pharmgen Sciences capabilities in drug development, regulatory approval, and commercialization to broaden its business scope in regenerative medicine and biopharmaceuticals. Founded in 2017, TS Bio is a biotechnology company specializing in research and development of cell therapies and gene therapies based on immune cells and stem cell technologies. The company operates a cell storage business utilizing facilities that meet Good Manufacturing Practice (GMP) standards and is actively engaged in regenerative medicine-related projects, enhancing its technical and business capabilities in the field. The two companies plan to collaborate in various areas, including sharing information on clinical pipelines in regenerative medicine and biopharmaceuticals, joint research efforts, evaluating the feasibility of new drug development and clinical applications, and establishing strategies for commercialization, manufacturing, and distribution. A representative from Pharmgen Science stated, We will play a leading role in enhancing the practical commercialization potential of our development achievements based on our accumulated experience in regulatory approval and commercialization, thereby strengthening our competitiveness in the fields of regenerative medicine and biopharmaceuticals. The regenerative medicine industry is experiencing rapid growth, with cell therapies and gene therapies serving as key growth drivers. Development of immune cell-based therapies is also progressing vigorously, with thousands of clinical trials reportedly underway globally, and the domestic regenerative medicine market is expanding as well. A Pharmgen Science official remarked, This agreement marks an important milestone in the companys mid-to-long-term growth strategy, and we aim to create new business opportunities through our expansion into regenerative medicine and biopharmaceuticals.* This article has been translated by AI. June 9, 2026 10:51 -
Pharos Ai Bio Partners with Eli Lilly on AI Drug Development Platform Pharos Ai Bio is collaborating with global pharmaceutical company Eli Lilly on its artificial intelligence (AI) drug development platform. This partnership marks the first instance of a domestic AI drug development firm connecting its capabilities with Eli Lillys AI drug development collaboration platform.On June 9, Pharos Ai Bio announced that it has signed a strategic cooperation agreement with Eli Lilly for the Lilly TuneLab, a drug development platform utilizing federated learning technology based on NVIDIA FLARE, which was launched by Eli Lilly in September of last year.The collaboration aims to enhance Pharos Ai Bios own AI drug development platform, Chemiverse®, by integrating its experience in drug candidate discovery and clinical development with the AI/ML model drug development systems of a global pharmaceutical leader, setting a precedent among domestic AI drug development companies.A representative from Pharos Ai Bio stated, Through this collaboration, we plan to enhance the Chemiverse platform and accelerate pipeline development while increasing the probability of success, thereby strengthening our global competitiveness.The strategy involves broadening the scope of collaboration with Lilly TuneLab based on the drug candidates, experimental data, and development know-how accumulated through Chemiverse, while continuously seeking joint research and technology commercialization opportunities with global pharmaceutical companies.Lilly TuneLab serves as a new pillar of AI/ML collaboration within Eli Lillys global open innovation platform, Catalyze360. It is the first AI federated learning drug development platform led by a global pharmaceutical company, built to connect the vast drug development research big data and AI/ML models accumulated through over $1 billion in investments by Eli Lilly over the past several decades with global innovative firms like Schrödinger.Through this partnership, Pharos Ai Bio plans to examine the properties, drugability, and development feasibility of key pipelines by linking the drug candidates and development strategies secured through Chemiverse with the AI/ML predictive environment of Lilly TuneLab.A Pharos Ai Bio official explained, The significance of this collaboration lies in the fact that it provides a starting point for validating the success potential and development feasibility of drug candidates and clinical development know-how already secured through our own platform within a global AI/ML collaborative framework.The use of AI in drug development is rapidly expanding. In the pharmaceutical and biotech sectors, AI is being utilized throughout the entire drug development cycle, from basic research to post-approval drug reassessment, significantly reducing development time and costs.Market growth is also noteworthy. According to a report by the Korea Research Institute of Chemical Technology (KRICT), the AI drug development market is projected to grow from $1.8 billion in 2024 to $6.8 billion by 2029.* This article has been translated by AI. June 9, 2026 09:54 -
Medytox Accelerates Global Distribution of 'Newraderm' in Europe and Asia Medytoxs neurodermal cosmetic brand, Newraderm, is accelerating its global expansion by securing distribution networks in Europe following its success in Asia.On June 8, Medytox announced that it has signed an exclusive supply agreement with Greeces Asklipios Medical Group (AMG), a medical device and cosmetics distribution company.With this agreement, Newraderm will expand its reach to seven European countries, including Greece, Italy, Spain, and France, in addition to its existing presence in Japan, Vietnam, Indonesia, and Hong Kong.Medytox plans to leverage AMGs distribution network to establish various online and offline sales channels, gradually increasing its market presence in Europe.A Medytox representative expressed optimism, stating, This exclusive supply agreement with AMG will serve as a strategic foundation for Newraderms global business expansion. The representative added, We will focus our efforts on establishing Newraderm as a leading global brand representing K-derma cosmetics.Meanwhile, Medytox is actively working to expand its distribution networks in global markets, including Europe and Asia. Following last years distribution agreements in Japan, Vietnam, and Indonesia, the company selected Hong Kong as its fourth overseas market through a contract with ColorMix in April.This agreement allows Newraderm to be exclusively supplied and distributed through ColorMixs extensive network, which includes over 60 stores across Hong Kong and Macau.Additionally, Medytox has been diversifying its business by targeting the cosmetics market with Newraderm in 2023. Newraderm is a neurodermal cosmetic brand developed based on Medytoxs over 20 years of research in botulinum toxin formulations, combining its expertise in neuroscience and dermatology with its proprietary technology, M.Biome.* This article has been translated by AI. June 8, 2026 17:36 -
Medical Association Discusses Key Healthcare Issues at 2026 Conference Amid ongoing turmoil in the medical community due to conflicts between physicians and the government over the past two years, a forum is set to discuss the future direction and key policy issues in healthcare. The Korean Medical Association announced on June 8 that it will hold the 2026 Korean Medical Association Conference on June 12 at the Plenty Convention Center, outlining the main agenda and session structure for the event. The conference, themed Communication and Empathy: Opening a New 60 Years, will address critical healthcare policy issues, including residency training for medical professionals, physician workforce projections, the sustainability of academic medicine in South Korea, and patient safety related to drug side effects. Lee Jin-woo, President of the Korean Medical Association, stated, Although the conference is taking place amid difficulties due to the conflicts over the past two years, this year marks the first conference since some resolutions have been reached. We have created a platform to discuss the direction the medical community should take and various unresolved issues, including regional and essential healthcare. The keynote address will be delivered by Song Ho-geun, a distinguished professor at Hallym University, who will discuss The Calling of Physicians and Healthcare Policy: The Curse of Success? He will diagnose the institutional contradictions that have accumulated behind the achievements of South Korean healthcare and suggest future directions for the medical field. The conference will feature eight session programs consisting of presentations and panel discussions. The Korean Medical Association will host sessions on The Future Direction of Residency Training in Korea and What Regional Healthcare Policies Can Deliver Immediate Results? Additionally, the Korean Medical Associations Medical Policy Research Institute will explore Seeking Desirable Physician Workforce Projections, while the Korean Association of Basic Medical Sciences will discuss New Horizons in Basic Medicine: Utilizing National Integrated Bio Big Data and AI. The Korean Academy of Medical Sciences will address How to Sustain Academic Medicine in South Korea? Other joint sessions will include topics such as Regional Physician System and Medical Education Accreditation by the Korean Institute of Medical Education and Evaluation, Drug Side Effects and Compensation: The Role of Healthcare in Ensuring Patient Safety by the Ministry of Food and Drug Safety, and HTA Paradigm Shift: Balancing Innovation and Sustainability in Medical Technology Assessment by the Korea Health and Medical Research Institute. The Korean Medical Association plans to link the discussions from the conference to forums, public hearings, and white paper publications to facilitate actual policy discussions and institutional improvements.* This article has been translated by AI. June 8, 2026 17:33